Skip to content
Clinical Trials – home

Hospital Universitari General De Catalunya

Research site

Spain Calle Pedro I Pons 1, 08195 Barcelona, Spain

  • 3 trials recruiting
  • Breast cancer · Dementia Alzheimer's type · Diabetic retinal oedema
  • Adults and children

About Specializations

Hospital Universitari General De Catalunya in Barcelona, Spain specialises in clinical trials of conditions such as Breast cancer, Dementia Alzheimer's type, Diabetic retinal oedema, Dry age-related macular degeneration, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle Pedro I Pons 108195 BarcelonaSpain
Recruiting now
3 trials
Conditions studied
12

More sites in BarcelonaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Study on the Safety and Effects of ACI-7104.056 in Patients with Early Parkinson's Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:AC Immune S.A.

Study on Elacestrant and Triptorelin for Premenopausal Women with Early Luminal Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tamoxifen Citrate
  • Sponsor:Solti Group

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:Clesrovimab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Solti Group

Study on the Effects of ABBV-552 in Patients Aged 50-90 with Mild Alzheimer's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(4R)-1-[(5-Chloro-1H-1,2,4-Triazol-1-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)-2-Pyrrolidinone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on JNJ-81201887 for Treating Geographic Atrophy in Age-related Macular Degeneration Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Study on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing OXU-001 and Intravitreal Dexamethasone for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Oxular IE Limited

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Regeneron Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.